Abstract
Cross-sectional studies have demonstrated that obstructive sleep apnoea (OSA) and metabolic syndrome (MetS) are often associated, but whether a temporal relationship exists is unknown. We aimed to investigate the effect of OSA on the risk of developing MetS in the general population. A prospective study was conducted combining two population-based samples: Episono (Brazil) and HypnoLaus (Switzerland). MetS was assessed according to the Joint Interim Statement. Polysomnography (PSG) was performed at baseline and follow-up in Episono, and at baseline in HypnoLaus. OSA was defined according to apnoea-hypopnoea index as mild (5.0–14.9/h) and moderate-to-severe (≥15.0/h). We included 1853 participants (52±13 years, 56% female) without MetS at baseline. After 6±1 years, 318 (17.2%) developed MetS. Moderate-to-severe OSA was independently associated with incident MetS (OR=2.58 [1.61–4.11]) and increased the number of MetS components from baseline to follow-up through mediation of %time spent with oxygen saturation <90%. Subset analysis in Episono confirmed that the increase in this parameter between baseline and follow-up PSGs represented a risk factor for incident MetS (OR=1.42 [1.04–1.95] for each 10% increase). In conclusion, OSA is independently associated with an increased risk of developing MetS through mediation of nocturnal hypoxaemia in the general population.
Footnotes
This manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.
Conflict of interest: Dr. Camila Hirotsu has nothing to disclose.
Conflict of interest: Dr. HABA-RUBIO has nothing to disclose.
Conflict of interest: Dr. Togeiro has nothing to disclose.
Conflict of interest: Dr. Marques Vidal has nothing to disclose.
Conflict of interest: Dr. Drager has nothing to disclose.
Conflict of interest: Dr. Vollenweider reports grants from GlaxoSmithKline, during the conduct of the study.
Conflict of interest: Dr. Waeber has nothing to disclose.
Conflict of interest: Dr. Bittencourt has nothing to disclose.
Conflict of interest: Dr. Tufik has nothing to disclose.
Conflict of interest: Dr Heinzer reports receiving fees as member the medical advisory boards of Nightbalance and Rythm compagnies as well as grants from Leenaards foundation and the Ligue pulmonaire vaudoise.
This is a PDF-only article. Please click on the PDF link above to read it.
- Copyright ©ERS 2018